Fresenius SE & Co. KGaA (FRA:FRE) received a €55.95 ($65.82) target price from equities research analysts at Berenberg Bank in a research report issued to clients and investors on Wednesday, Borsen Zeitung reports. Berenberg Bank’s price objective would suggest a potential upside of 35.42% from the stock’s current price.
A number of other analysts have also recently weighed in on FRE. Jefferies Financial Group set a €39.00 ($45.88) price target on Fresenius SE & Co. KGaA in a research report on Friday, July 30th. Morgan Stanley set a €47.00 ($55.29) price target on Fresenius SE & Co. KGaA in a research report on Wednesday, July 14th. Nord/LB set a €52.00 ($61.18) price target on Fresenius SE & Co. KGaA in a research report on Tuesday, August 10th. Deutsche Bank Aktiengesellschaft set a €39.00 ($45.88) price target on Fresenius SE & Co. KGaA and gave the company a “neutral” rating in a research note on Thursday, June 17th. Finally, The Goldman Sachs Group set a €49.00 ($57.65) price target on Fresenius SE & Co. KGaA in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Fresenius SE & Co. KGaA currently has a consensus rating of “Buy” and a consensus target price of €48.38 ($56.92).
Shares of FRA FRE opened at €41.32 ($48.61) on Wednesday. The stock’s 50 day moving average price is €44.37 and its two-hundred day moving average price is €42.55. Fresenius SE & Co. KGaA has a 52-week low of €60.16 ($70.78) and a 52-week high of €80.00 ($94.12).
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Featured Story: What are Bollinger Bands?
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.